{
    "root": "35d397f3-82fe-9079-e063-6294a90af13b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20250523",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        }
    ],
    "indications": {
        "text": "pregabalin indicated : \u2022 management neuropathic pain associated diabetic peripheral neuropathy \u2022 management postherpetic neuralgia \u2022 adjunctive therapy treatment partial-onset seizures patients 1 month age older \u2022 management fibromyalgia \u2022 management neuropathic pain associated spinal cord injury",
        "doid_entities": [
            {
                "text": "peripheral neuropathy (DOID:574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_574"
            },
            {
                "text": "neuropathy (DOID:870)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_870"
            },
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adult , begin dosing 150 mg/day . partial-onset seizure dosing pediatric patients 1 month age older , refer section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14mg/kg/day . fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . dose adjusted adult patients reduced renal function . ( 2.7 )",
        "doid_entities": [
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "150 mg capsules : white hard gelatin capsules , imprinted black ink \u2018 a011 \u2019 cap \u201c preg 150 \u201d body ; available : ndc 60760-682-30 bottles 30 storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "pregabalin contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "indications_original": "Pregabalin is indicated for:\u00a0 \n    \u2022\n \n  \u00a0Management of neuropathic pain associated with diabetic peripheral neuropathy\u00a0 \n    \u2022\u00a0Management of postherpetic neuralgia\u00a0 \n    \u2022\u00a0Adjunctive therapy for the treatment of partial-onset seizures in patients\u00a01 month of age and older\u00a0 \n    \u2022\u00a0Management of fibromyalgia \n    \u2022\u00a0Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4. ( 2.2, 2.3, 2.4, 2.5, 2.6 ) Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week.\u00a0 Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More \u00a0( 2.4 ) 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric Patients Weighing Less than 30 kg ( 2.4 ) 1 month to less than 4 years: 3 divided doses per day 4 years and older : 2 or 3 divided doses per day 14mg/kg/day. Fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week.\u00a0 Maximum dose of 600 mg/day. Dose should be adjusted in adult patients with reduced renal function. ( 2.7 )",
    "warningsAndPrecautions_original": "150 mg capsules:\n                  \n                  \n                  White hard gelatin capsules, imprinted with black ink \u2018A011\u2019 on the cap and \u201cPREG 150\u201d on the body; available in:\n                  \n                  NDC 60760-682-30 BOTTLES OF 30\n                  \n                     \n                  \n                  \n                  \n                  \n                  Storage and Handling\n                  \n                  \n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy\n \n  [see Warnings and Precautions (\n  \n   5.2)].",
    "drug": [
        {
            "name": "Pregabalin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        }
    ]
}